Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Organon Foresees US Adalimumab Discounts Hitting 80%-90%
CEO Suggests Heavy Competition Will Lead To Steep Price Cuts By 2025-2026
Jan 11 2023
•
By
David Wallace
Humira biosimilar discounts could be substantial by 2025-2026 • Source: Shutterstock
More from Biosimilars
More from Products